MDXG Stock Analysis: Buy, Sell, or Hold?
MDXG - MiMedx Group, Inc
$4.33
0.03 (0.70%)
â˛
5d:
+1.41%
30d:
+4.84%
90d:
+19.94%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Get Alerted When MDXG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MDXG is fairly priced but lacks strong directional signals. At -2.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MDXG is fairly priced but lacks strong directional signals. At -2.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: MDXG is currently trading at $4.33, which is considered fair relative to its 30-day fair value range of $4.17 to $4.34. The stock's valuation (Forward PE: 25.0) is in line with its historical norms (27.1). Remarkably, the market is currently pricing in an annual earnings decline of 2.7% over the next few years. This pessimistic expectation contrasts with the company's recent 99.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, MDXG is in a strong uptrend. Immediate support is located at $4.12, while resistance sits at $4.50.
Market Sentiment: MDXG scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+61.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MDXG is in a strong uptrend. Immediate support is located at $4.12, while resistance sits at $4.50.
Market Sentiment: MDXG scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+61.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.17 -
$4.34
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 61.7% below Wall St target ($7.00)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.17 -
$4.34
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.12
Resistance Level
$4.50
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.99
Wall Street Target
$7.00
(+61.7%)
Revenue Growth (YoY)
-34.7%
Earnings Growth (YoY)
99.5%
Profit Margin
1.8%
Valuation Discount vs History
-2.7% cheaper
PE vs Historical
25.0 vs 27.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.7%
(market-implied from PE analysis)
1-Year Target
$4.21
(-3%)
2-Year Target
$4.10
(-5%)
3-Year Target
$3.99
(-8%)
3-Yr Target (if PE normalizes)
(PE: 25â27)
$4.33
(0%)
đ
Valuation based on Current Earnings
Forward PE: 19.53 | Forward EPS (Implied): $0.22
Bull Case
$5.23
(+21%)
Analyst growth 15.0%, PE expands to 20.5
Base Case
$4.33
(0%)
Market implied 0.0%, PE stable at 19.5
Bear Case
$3.31
(-24%)
Severe decline -15.0%, PE contracts to 17.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 25.0 to 27.1
Stabilization Target:
$4.70
(+8.5%)
PE Expansion Potential:
+8.5%
Share & Embed Analysis
Last updated: August 23, 2026 9:14 PM ET
Data refreshes hourly during market hours. Next update: 10:14 PM
Data refreshes hourly during market hours. Next update: 10:14 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDXG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
